Healthcare & Pharmaceuticals
🟢 SERP-Grounded (Light Telemetry)
Incyte
Programmatic AI Search & Model Visibility Audit
Share of Model (SOM)The percentage of time frontier AI models (ChatGPT, Claude, Gemini) recommend this brand for high-intent category queries.
28.0%
+1.0% 30-Day MomentumThe rolling 30-day change in algorithmic Share of Model. Positive momentum indicates increasing AI mindshare.
🧠 Neural Valency:NeutralThe contextual sentiment of the AI's recommendation. 'Dominant' implies strong conviction, while 'Vulnerable' implies the model heavily conditions its recommendation.
Algorithmic Threat Detection
Primary Competitor Threat
Gilead Sciences
Competitor Displacement Rate
15.0%
Competitors are displacing Incyte in 15.0% of high-intent buyer queries.The frequency at which AI models actively suggest a competitor as a superior alternative to this brand.
Algorithmic Rationale: Incyte's position is threatened by Gilead Sciences' broader portfolio of targeted therapies and established market presence. Gilead has a stronger pipeline and market penetration.
Missing AI Citations:High-authority domains (e.g., Reddit, G2) that models cite to justify recommending competitors, where this brand currently lacks presence.
[novartis.com][pfizer.com]⚠️ Identified Vulnerability:Pipeline Diversity
Primary Threat Identified:Gilead Sciences
Target Persona:Hematologists
🚨 Threat Velocity:6/10An algorithmic urgency score (1-10) indicating how rapidly competitors are capturing this brand's historical AI search share.
Unlock Full Threat Report (30 Free Credits)